Clinical trials: Super-refractory Status Epilepticus
Status Epilepticus, Convulsive Status Epilepticus
Predictors of Outcomes of Convulsive Status Epilepticus
Status epilepticus is a life-threatening neurological emergency characterized by prolonged seizures or multiple seizures occurring without the patient regaining consciousness between episodes.
- Trial name
- NCT07853391
- Volunteers
- 100 people
- Sponsor
- Assiut University
Super-Refractory Status Epilepticus
An Open Label, Expanded Access Protocol With SAGE-547 for Super-Refractory Status Epilepticus
This is an open-label, expanded access protocol, designed to offer treatment with SAGE-547 to subjects in SRSE, and to evaluate the efficacy and safety of SAGE-547 administered as a continuous intravenous infusion to these…
- Trial name
- NCT02433314
- Testing
- SAGE-547
- Sponsor
- Supernus Pharmaceuticals, Inc.
Status Epilepticus, Cardiac Arrest
Dual Anti-glutamate Therapy in Super-refractory Status Epilepticus After Cardiac Arrest
Status epilepticus (SE) is found in 20-30% of patients in coma after cardiac arrest, is often refractory to medical therapy and is considered a negative prognostic factor.
- Trial name
- SUPER-CAT (NCT05756621)
- Testing
- Ketamine, Any anti-epileptic and anesthetic therapy, excluding Ketamine and Perampanel
- Where
- 10 sites in Italy
- Volunteers
- 84 people
- Sponsor
- University of Milano Bicocca
Super-Refractory Status Epilepticus
A Study With SAGE-547 for Super-Refractory Status Epilepticus
This is a randomized, double-blind, placebo-controlled trial, designed to evaluate the efficacy and safety of SAGE-547 administered as a continuous intravenous infusion to subjects in Super-Refractory Status Epilepticus (SRSE).
- Trial name
- NCT02477618
- Testing
- SAGE-547
- Where
- 171 sites in United States, Austria and 14 more
- Volunteers
- 132 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Super-refractory Status Epilepticus
Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus
The purpose of this study is to evaluate the safety and tolerability of SAGE-547 in participants in super-refractory status epilepticus (SRSE).
- Trial name
- SRSE (NCT02052739)
- Testing
- SAGE-547
- Where
- 17 sites in United States
- Volunteers
- 25 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Refractory Status Epilepticus
Multicenter Retrospective Study of Isoflurane in Refractory and Super-Refractory Status Epilepticus
Isoflurane might be used as anticonvulsive therapy in refractory status epilepticus. The aim of the study is to assess the efficiency of Isoflurane in this indication.
- Trial name
- I-Seizure (NCT05830864)
- Testing
- Isoflurane
- Where
- 4 sites in France
- Volunteers
- 66 people
- Sponsor
- Hopital of Melun
Status Epilepticus
SURESTEP: Transcranial Direct Current Stimulation in Super Refractory Status Epilepticus
The purpose of this study is to determine whether transcranial direct current stimulation affects super refractory status epilepticus.
- Trial name
- SURESTEP (NCT03819543)
- Testing
- Transcranial Direct Current Stimulation
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- University of Manitoba
Super-refractory Status Epilepticus
KD Treatment for Super-refractory Status Epilepticus
The purpose of the study is to investigate to evaluate the efficacy and safety of ketogenic diet (KD) as an adjunctive therapy in patients with Super Refractory Status Epilepticus (SRSE) in the intensive care unit (ICU).
- Trial name
- KD (NCT07496749)
- Testing
- the ketogenic diet, Standard Medical Therapy
- Where
- 14 sites in China
- Volunteers
- 84 people
- Sponsor
- Xuanwu Hospital, Beijing